Kawaguchi Takae, Hashimoto Rina, Yasukawa Youko, Yamada Shusaku, Yoshimura Aritada, Hirao Daiki, Ohmori Takahiro, Fukushima Ryuji
Tokyo University of Agriculture and Technology Animal Medical Center, 3-5-8 Saiwai-cho, Fuchu-shi, Tokyo 183-8509, Japan.
J Vet Med Sci. 2019 May 31;81(5):717-722. doi: 10.1292/jvms.18-0772. Epub 2019 Apr 8.
Maintaining a good ventricular systolic function is important in the long-term therapy of dogs with supraventricular tachyarrhythmia (SVTA). The objective of this study was to evaluate the inhibitory effect of telmisartan on myocardial injury and the resulting ventricular systolic dysfunction in a canine model of SVTA. A total of 14 dogs were randomly assigned to a Telmisartan (oral telmisartan, 1.0 mg/kg daily, n=7) or a Control (no drug administration, n=7) group; the duration of rapid atrial pacing (RAP) was 3 weeks for both groups. The cardiac troponin I (cTnI) concentration in the Control group was significantly increased after 3 weeks compared to that before RAP initiation (baseline), but no significant difference was observed in the Telmisartan group. Moreover, the cTnI concentration at 3 weeks was significantly lower in the Telmisartan group than in the Control group. The left ventricular fractional shortening was significantly decreased at 3 weeks compared to that at baseline in both groups. However, fractional shortening at 3 weeks was significantly higher in the Telmisartan group than in the Control group. The cardiac output values in the Control group were significantly decreased at 3 weeks compared with those at baseline, but no significant difference was observed in the Telmisartan group. This study demonstrates that telmisartan inhibits the reduction in ventricular systolic function and prevents myocardial injury in a canine model of SVTA. Therefore, telmisartan is suggested as a novel treatment for canine SVTA.
维持良好的心室收缩功能对于室上性快速心律失常（SVTA）犬的长期治疗至关重要。本研究的目的是评估替米沙坦对SVTA犬模型中心肌损伤及由此导致的心室收缩功能障碍的抑制作用。总共14只犬被随机分为替米沙坦组（口服替米沙坦，每日1.0 mg/kg，n = 7）或对照组（不给予药物，n = 7）；两组快速心房起搏（RAP）的持续时间均为3周。与RAP开始前（基线）相比，对照组3周后的心肌肌钙蛋白I（cTnI）浓度显著升高，但替米沙坦组未观察到显著差异。此外，替米沙坦组3周时的cTnI浓度显著低于对照组。两组3周时的左心室缩短分数均较基线时显著降低。然而，替米沙坦组3周时的缩短分数显著高于对照组。对照组3周时的心输出量值与基线时相比显著降低，但替米沙坦组未观察到显著差异。本研究表明，替米沙坦可抑制SVTA犬模型中心室收缩功能的降低并预防心肌损伤。因此，建议将替米沙坦作为犬SVTA的一种新的治疗方法。
